Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Oruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tol
How this was made
The 30-second read
Why it matters
The data suggest a high likelihood of regulatory engagement and Phase 3 initiation in H1 2027, which could materially affect valuation.
Market read
Positive trial data are a catalyst for ORKA's stock, with potential upside ahead of Phase 3 planning.
What to watch
Potential competition from other IL‑23 candidates and reimbursement uncertainty.
Background
Oruka Therapeutics (Nasdaq: ORKA) announced Phase 2b trial results for its IL‑23p19 antibody ORKA‑001 in moderate‑to‑severe psoriasis.
Ticker impact
Oruka Therapeutics disclosed positive Week 16 Phase 2b data for ORKA-001, showing 61% PASI 100 and 86% PASI 90 in the high‑dose group.
upward pressure as market prices in the strong efficacy and upcoming Phase 3 initiation
Phase 2b results are material, first‑time disclosure, and indicate a competitive advantage in the IL‑23 space, prompting buy‑side interest.
Market effects
May boost sentiment for IL‑23 biologics and other psoriasis therapeutics.
US biotech sector could see modest gains.
Limited to biotech investors; no broad market effect.
Counterpoint
If Phase 3 fails to replicate durability, the hype could reverse sharply.
Key entities
- companyOruka Therapeutics
Clinical‑stage biotech developing ORKA‑001.
- personJoel Gelfand
Lead investigator for the EVERLAST‑B trial.
